Form 4: Ocular Therapeutix Executive Receives Stock Options and Restricted Stock Units

Todd Anderman, Chief Legal Officer of Ocular Therapeutix, Inc., was granted stock options and restricted stock units (RSUs) on October 7, 2024.

Summary

• On October 7, 2024, Todd Anderman, the Chief Legal Officer of Ocular Therapeutix, Inc., received 98,700 restricted stock units (RSUs) and options to purchase 296,500 shares of common stock.
• The RSUs vest in equal annual installments over three years, starting on the grant date.
• The stock options vest over four years, with 25% vesting on the one-year anniversary of employment and the remainder vesting monthly thereafter.
• The exercise price for the stock options is $9.48, and they expire on October 6, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard executive compensation practices, aligning management interests with shareholders.

Positives

• The grant of RSUs and stock options aligns the executive's interests with those of the shareholders.
• The vesting schedules incentivize continued service to the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the granted securities.

Industry Context

Equity compensation is a common practice in the biotechnology industry to attract, retain, and incentivize key executives.

Comparison to Industry Standards

• Equity grants are a standard component of compensation packages for executives in publicly traded companies, particularly in the biotech sector.
• Vesting schedules, such as the three-year annual vesting for RSUs and four-year vesting for stock options, are typical in the industry to ensure long-term commitment.
• Comparable companies like Alnylam Pharmaceuticals or Vertex Pharmaceuticals also utilize stock options and RSUs as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign, aligning management's interests with the company's long-term success.
• Employees may see the grants as a sign of confidence in the company's future.

Key Dates